Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > REGULATORY
REGULATORY
- LDP Health Panel Chair Submits Letter Opposing Annual Price Revisions
December 13, 2016
- PMDA Reviewing Risk of Hep B Virus Reactivation for Revlimid
December 13, 2016
- MHLW Announces 16 APIs as Candidates for Switch-OTC Status: None for Lifestyle Diseases
December 13, 2016
- MHLW Panel Recommends 3 Products Including Talion for Approval as “Behind-the-Counter Drugs”
December 13, 2016
- Balance between Survey Costs and Price Gap Important, Shiozaki Says on Annual Revisions
December 12, 2016
- HIV Med Descovy Approved in Japan
December 12, 2016
- Industry Casts Doubt on “1.25 Times” Threshold for Downward Tweak under Foreign Price Adjustment Rule
December 12, 2016
- Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
December 12, 2016
- Health Minister Calls for Structural Change in Pharma Industry
December 12, 2016
- The Sooner the Better, Suga Says on Drug Pricing Revamp
December 12, 2016
- Industry’s “No” to Disclosure of Manufacturing Costs Draws Fire from Chuikyo Reps
December 12, 2016
- (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
December 12, 2016
- Shiozaki Will Bring Chuikyo’s Views to 4-Way Confab, No Paper Planned: Official
December 12, 2016
- (Update) Pharma Trade Groups Express Strong Opposition to Annual Price Revisions: Chuikyo
December 12, 2016
- Ruling Parties Compile FY2017 Tax Reform Package, R&D Tax Credit Revamp Specified
December 9, 2016
- Healthcare-Related LDP Legislators Criticize Annual Revisions
December 9, 2016
- Govt Eyes “Bailout Measures” for Products with Small NHI-Market Price Gaps in Annual Revision Plan
December 9, 2016
- Talion AG, 2 Other APIs Skip December Gx Listing
December 8, 2016
- First Generics for 5 APIs to Join NHI Price List on Dec. 9
December 8, 2016
- Shiozaki, Govt Panel Agree on Annual Price Reviews, but Scope of Drugs Still Unclear
December 8, 2016
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…